Advertisement

Corroboration equals collaboration

  • Victoria M. Robinson
    Affiliations
    Division of Cardiovascular Sciences, The University of Manchester, Manchester, United Kingdom

    Cardiovascular Research, The Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
    Search for articles by this author
  • Munveer Thind
    Affiliations
    Cardiovascular Research, The Lankenau Institute for Medical Research, Wynnewood, Pennsylvania
    Search for articles by this author
  • Peter R. Kowey
    Correspondence
    Address reprint requests and correspondence: Dr Peter R. Kowey, Lankenau Heart Institute Administrative Offices, Lankenau MOB East Suite 356, 100 Lancaster Avenue, Wynnewood, PA 19096.
    Affiliations
    Cardiovascular Research, The Lankenau Institute for Medical Research, Wynnewood, Pennsylvania

    Department of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania
    Search for articles by this author
Published:January 22, 2021DOI:https://doi.org/10.1016/j.hrthm.2021.01.020
      Nowhere in medicine has the data explosion been more evident than in cardiology. The increase in the number of subspecialties has generated a multitude of journals eager to capture the highest-profile articles. Because of the deluge of data, numerous doctors have fallen prey to literature surfing. Many have chosen to read abstracts or secondary literature in which a physician “expert” summarizes the findings of an important trial. The situation is exacerbated by topline reporting of pivotal clinical trials by industry sponsors, fearing class action lawsuits, before any of the data are presented. Presentations at high-profile international meetings are often not accompanied by simultaneous publications.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kirchhof P.
        • Camm A.J.
        • Goette A.
        • et al.
        Early rhythm-control therapy in patients with atrial fibrillation.
        N Engl J Med. 2020; 383: 1305-1316
        • Wyse D.G.
        • Waldo A.L.
        • DiMarco J.P.
        • et al.
        A comparison of rate control and rhythm control in patients with atrial fibrillation.
        N Engl J Med. 2002; 347: 1825-1833
        • Marrouche N.F.
        • Brachmann J.
        • Andresen D.
        • et al.
        Catheter ablation for atrial fibrillation with heart failure.
        N Engl J Med. 2018; 378: 417-427
        • Packer D.L.
        • Mark D.B.
        • Robb R.A.
        • et al.
        Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial.
        JAMA. 2019; 321: 1261-1274
        • Yang E.
        • Tang O.
        • Metkus T.
        • et al.
        The role of timing in treatment of atrial fibrillation: an AFFIRM substudy.
        Heart Rhythm. 2021; 18: 674-681
        • Guo Y.
        • Lane D.A.
        • Wang L.
        • et al.
        Mobile health technology to improve care for patients with atrial fibrillation.
        J Am Coll Cardiol. 2020; 75: 1523-1534

      Linked Article